Emerald Health Targets Endocannabinoid System

Recently the editors of US Daily Review visited with Emerald Health to learn more about this unique player in its industry. 
US DAILY REVIEW: When did Emerald Health start and how? Emerald Health Bioceuticals launched in 2017 as a subsidiary company of Emerald Health Sciences – a group of global leaders working to develop innovative pharmaceutical, botanical and nutraceutical products that interact with the human endocannabinoid system (ECS).  Prior to launch, they met with me about creating a brand in the US. With all of the legal challenges surrounding CBD and cannabis at the time, I challenged the Emerald Health Sciences Advisory Board, comprised of some of the world’s leading experts in natural medicine and endocannabinoid science, to find an alternative way for consumers to target the endocannabinoid system, like CBD and THC, but without the cannabis. 

After conducting a meta analysis of 4000 studies, the creation of Emerald Health’s propriety PhytoCann® Complex was born. The PhytoCann® Complex is the only doctor-formulated and cannabis-free blend of six herbal and botanical extracts (clove, Szechuan pepper, ginger, Echinacea, peony and magnolia) in precise potencies and ratio that target the ECS. The complex serves as the foundation behind our award-winning Endo line of condition-specific products that target consumers most common health concerns including inflammation, sleep, stress, mood and cognition (and soon-to-be released immune). This innovation launched the company we have today, with the mission to provide the most advanced products on the market that activate and nourish the powerful ECS system – keeping the mind and body in nature’s perfect balance.


US DAILY REVIEW: What’s the endocannabinoid system and how does it work?

The endocannabinoid system (ECS) has only been recently discovered in modern science, but it’s actually a 600-million-year-old receptor-site system that promotes biological balance in every cell, tissue and organ. Your ECS is responsible for regulating nearly everything including inflammation, mood, appetite, cognition, energy, metabolism, stress response and more – making it a vital system to support. It’s especially important to support in today’s fast-paced (and often imbalanced) world. Because CBD is so popular, ECS is becoming the next big thing in health and wellness and rightfully so.
The ECS can be activated by endocannabinoids (produced naturally inside the body), with phytocannabinoids (plant-based cannabinoids that mimic those produced in the body) and with cannabimimetics (cannabinoid mimicking compounds). All three cannabinoids bind to receptor sites throughout the body, like a key does to a lock, releasing important neurotransmitters that communicate vital information to the mind and body, promoting homeostasis (or balance). Additionally, lifestyle factors, like exercising, meditating, practicing yoga and eating a balanced, whole-foods diet, can all support this powerful and essential system.


US DAILY REVIEW: You have won many awards, which do you consider the most significant and why?

We feel very honored that the natural products industry recognizes us and our endocannabinoid support supplements as leaders in wellness and ECS health. Each accolade we’ve won has been significant in helping us bring awareness and expansion to the growing category of endocannabinoid health – beyond CBD and cannabis. From receiving the Nexty Awards Editor’s Choice for best new supplement or winning the Taste for Life Essentials Award for Endo Bliss and Endo Inflame to winning the Remedies Stress Award for Endo Calm, each award signifies an acknowledgement from the industry that there are other herbs and botanicals that can activate and support the endocannabinoid system just as effectively as hemp or cannabis, as well as a readiness and hunger for what’s next in ECS health. 

US DAILY REVIEW: What makes you different?

Our line of products offers a new and comprehensive way to address consumer’s most common health concerns by supporting the very important endocannabinoid system.  We mindfully formulate products using expertly-chosen ingredients and phytocannabinoids formulated specifically to target the endocannabinoid receptor system. Our new Endo Omega line of dietary omegas is the world’s first omega supplement exclusively formulated to provide the foundational building blocks needed to support the body’s production of omega-based endocannabinoids, which are essential for whole-body wellness. Additionally, for times where extra support is needed or during times of stress, depletion, or illness, our condition-specific ENDO line offers care for inflammation, sleep, anxiety, mood, immunity and cognition with cannabis-free herbal and botanical extracts. 
Our products provide a synergistic multi-pronged approach to helping consumers achieve optimal wellness through endocannabinoid health . We’re confident our products will work better than CBD alone or any other condition-specific product. Because of this, we offer an unconditional 30-day money back guarantee on every product.

US DAILY REVIEW: What are some final thoughts about your category? 

I believe the CBD as we know today (the primary descriptor on the front of product packaging to attract consumers) will fade and regulations will change. I think when this happens, people will focus on what’s important, which is the ECS system and ENDOCANNABINOID HEALTH. There’s much more to this story than just an isolate ingredient like CBD. Endocannabinoid health is a lifestyle choice and decision, sort of like people who live a vegan lifestyle. Many dietary, lifestyle and natural compounds impact the ECS in a positive way and because of this, the ECS lifestyle category will only continue to evolve and thrive. CBD raised awareness of the endocannabinoid system and for this we should be grateful. I expect to see the ECS health category expand and grow quickly in the next five years or so and will be on par with the Omega 3 category.

All opinions expressed on USDR are those of the author and not necessarily those of US Daily Review.